Face taping promises smoother skin and fewer wrinkles without injectables, but evidence suggests any visible benefits are largely temporary.
News|Articles|July 11, 2025
- Dermatology Times, July 2025 (Vol. 46. No. 07)
- Volume 46
- Issue 07
FDA News and Decisions: Midyear Updates
Author(s)Emma Andrus, Editor
Exclusive Report: A comprehensive look at the latest FDA approvals and pipeline developments in dermatology from the first half of 2025.
Advertisement
Advertisement
The first half of 2025 brought about numerous developments in dermatology, with key decisions from the FDA and a surge of activity across submissions, trial advancements, and regulatory actions driving the pipeline forward. To help you stay informed, we compiled an overview of FDA approvals and clearances, new filings, and other pivotal regulatory movements in the specialty from January through June.
Related to this article
Lutikizumab significantly improved HiSCR75 response, pain, and disease flares in adults and adolescents with moderate to severe HS.
Disc Medicine reports the phase 3 APOLLO trial met all primary and secondary end points, with whole-blood PPIX reduced 41.4% vs placebo and an NDA resubmission planned by end of 2026.
Castor oil has become a popular social media remedy for thicker, longer hair, but evidence supporting its ability to stimulate hair growth remains limited.
The FDA clearance allows Edesa to expand an ongoing placebo-controlled study of the CXCL10 antibody EB06 to US sites, with topline data expected in the fourth quarter of 2027.
The novel oral helicase-primase inhibitor demonstrated significantly higher rates of complete lesion healing compared with investigator’s choice treatment in the phase 3 PRIOH-1 trial.
Can “Botox in a bottle” really rival injectable neuromodulators? We examine the evidence behind topical peptide serums and Argireline.
Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.
Advertisement
Advertisement